Otsuka Pharmaceutical Co. Ltd.’s AVP-786 missed the primary endpoint for a third time in a phase III trial for agitation associated with dementia due to Alzheimer’s disease (AD). Two previous phase III trials also failed to show statistical significance for AVP-786.

New York-based Viewmind Inc. has applied for patent protection of methods and systems for detecting neurological disorders and/or measuring, fine-motor skills, processing speed, decision making, and cognitive processes by measuring eye movements, oculomotor features and pupil behavior.

Japanese researchers have developed a new rat model of thromboembolic ischemic stroke that did not require arterial ligation of the external carotid artery, which makes the research for thrombolytic agents more complicated.

Nonhuman primate (NHP) models may contribute to advance research in Alzheimer’s disease (AD) thanks to their genetic, anatomical and physiological similarities with humans. However, their use in AD research is limited by significant challenges, including long generation times, ethical considerations and technical challenges of genetic modification.

Researchers from the University of Queensland and affiliated organizations recently presented preclinical data for the novel C3a receptor (C3aR) antagonist JR-14a, being developed as a neuroprotective agent for the treatment of post-stroke neuroinflammation.

Elemind Technologies Inc. may not (yet) be telepathic, but the new company certainly read the mood of investors well as it secured $12 million in seed funding before emerging from stealth this week. While the product has yet to be fully revealed, the company is developing a wearable neurotechnology platform that uses artificial intelligence to read and guide brainwaves using tailored sound stimulation.